Objective
to examine if ticagrelor was superior to clopidogrel to reduce periprocedural myocardial necrosis during PCI
Study
phase 3b, open-label multicentre randomised trial
Population
patients with stable CAD at high-risk undergoing elective PCI
Endpoints
PCI related myocardial infarction (type 4A or 4B) or major myocardial injury within 48 h of the procedure
Conclusion
ticagrelor was not superior to clopidogrel in reducing periprocedural myocardial necrosis after elective PCI
Silvain et al. Lancet. 2020;396:1737-44
